I Want To...
I Want To...
Find Research Faculty
Enter the last name, specialty or keyword for your search below.
School of Medicine
I Want to...
Nancy A. Ator, Ph.D.
Director, Division of Behavioral Biology
Professor of Psychiatry and Behavioral Sciences
Research Interests: Behavioral pharmacology and drug abuse; Preclinical characterization of anxiolytics, hypnotics; In vivo characterization of selective GABAergic compounds to determine behavioral relevance of novel in-vitro activity with respect to drug abuse; Study of interoceptive stimulus functions of psychoactive drugs ...read more
- Director, Division of Behavioral Biology
- Professor of Psychiatry and Behavioral Sciences
Johns Hopkins University School of Medicine, Baltimore, Maryland, 1978
Research & Publications
Ator NA, Weerts EM, Kaminski, BJ, Kautz MA, Griffiths RR. Zaleplon and triazolam physical dependence assessed across increasing doses under a once-daily dosing regimen in baboons. Drug and Alcohol Dependence:61:69-84. (2000)
Ator NA, Kautz MA. Differentiating benzodiazepine and barbituate-like discriminative stimulus effects of lorazepam, diazepam, pentobarbital, imidazenil, and zaleplon in two versus three lever procedures. Behavioural Pharmacology:11:1-14. (2000)
Ator NA. Zaleplon and triazolam: Drug discrimination, plasma levels, and self-administration in baboons. Drug and Alcohol Dependence: 61:69-84. (2000)
Ator NA. Relation between discriminative and reinforcing effects of midazolam, pentobarbital, chlordiazepoxide, zolpidem, and imidazenil in baboons. Psychopharmacology: 163:477-487. (2002)
Ator NA, Griffiths RR. Principles of drug abuse liability assessment in laboratory animals. Drug and Alcohol Dependence: 70: S55-S72. (2003)
Ator NA. Contributions of GABAa receptor subtype selectivity to abuse liability and dependence potential of pharmacological treatments for anxiety and sleep disorders. CNS Spectrums:10: 31-39. (2005)
Ator, N. A., Atack, J. R., Hargreaves, R. J., Burns, H. D., and Dawson, G. R. (2010) Reducing abuse liability of GABAA/benzodiazepine ligands via selective partial-agonist efficacy at α1 and α2/3 subtypes. Journal of Pharmacology and Experimental Therapeutics, 332: 4-16. (Published online September 29, 2009; doi:10.1124/jpet.109.158303)